EA201390977A1 - Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона - Google Patents
Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсонаInfo
- Publication number
- EA201390977A1 EA201390977A1 EA201390977A EA201390977A EA201390977A1 EA 201390977 A1 EA201390977 A1 EA 201390977A1 EA 201390977 A EA201390977 A EA 201390977A EA 201390977 A EA201390977 A EA 201390977A EA 201390977 A1 EA201390977 A1 EA 201390977A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- opioid receptor
- parkinson
- disease
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Настоящим изобретением обеспечивается фармацевтическая лекарственная форма, включающая агонист опиоидных рецепторов и антагонист опиоидных рецепторов, для применения при лечении болезни Паркинсона. Настоящее изобретение также относится к применению агониста опиоидных рецепторов и антагониста опиоидных рецепторов в такой лекарственной форме.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10197210 | 2010-12-28 | ||
PCT/EP2011/074103 WO2012089738A1 (en) | 2010-12-28 | 2011-12-27 | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201390977A1 true EA201390977A1 (ru) | 2013-12-30 |
EA025747B1 EA025747B1 (ru) | 2017-01-30 |
Family
ID=43903970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390977A EA025747B1 (ru) | 2010-12-28 | 2011-12-27 | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона |
Country Status (19)
Country | Link |
---|---|
US (1) | US20140037729A1 (ru) |
EP (1) | EP2658523A1 (ru) |
JP (2) | JP5864606B2 (ru) |
KR (2) | KR101632858B1 (ru) |
CN (1) | CN103347495B (ru) |
AR (1) | AR084620A1 (ru) |
AU (1) | AU2011351447B2 (ru) |
BR (1) | BR112013016862A2 (ru) |
CA (1) | CA2822528C (ru) |
CL (1) | CL2013001943A1 (ru) |
EA (1) | EA025747B1 (ru) |
MX (1) | MX354125B (ru) |
MY (1) | MY162895A (ru) |
NZ (1) | NZ612837A (ru) |
SG (1) | SG191208A1 (ru) |
TW (2) | TWI554271B (ru) |
UA (1) | UA109301C2 (ru) |
WO (1) | WO2012089738A1 (ru) |
ZA (1) | ZA201304303B (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ603170A (en) | 2010-05-10 | 2015-04-24 | Euro Celtique Sa | Combination of active loaded granules with additional actives |
ES2642788T3 (es) | 2010-05-10 | 2017-11-20 | Euro-Celtique S.A. | Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos |
KR101632858B1 (ko) * | 2010-12-28 | 2016-06-22 | 유로-셀티큐 에스.에이. | 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물 |
US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
HUE052542T2 (hu) | 2011-04-29 | 2021-05-28 | Univ Rutgers | Eljárás diszkinézia kezelésére |
US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
WO2014004126A1 (en) * | 2012-06-26 | 2014-01-03 | Fleming C Andrew | Treating postoperative nausea and vomiting |
KR20180037074A (ko) | 2013-07-23 | 2018-04-10 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
CA2847781C (en) * | 2014-03-28 | 2019-03-12 | Purdue Pharma | Reducing drug liking in a subject |
US20150352099A1 (en) * | 2014-06-04 | 2015-12-10 | Mentinova Inc. | Compositions and Methods of Reducing Sedation |
EP3183232B1 (en) | 2014-08-22 | 2023-05-03 | The Arizona Board of Regents on behalf of The University of Arizona | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation |
WO2016116615A1 (en) * | 2015-01-23 | 2016-07-28 | Euro-Celtique S.A. | A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US20160256451A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Dosage of naloxone |
AU2016266432B2 (en) * | 2015-05-26 | 2020-10-22 | Laboratorio Medinfar-Produtos Farmacêuticos, S.A. | Compositions for use in treating Parkinson's disease and related disorders |
WO2018055199A1 (en) * | 2016-09-26 | 2018-03-29 | Euro-Celtique S.A. | Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio |
US20230343429A1 (en) * | 2019-10-31 | 2023-10-26 | The United States Government As Represented By The Department Of Veterans Affairs | Methods, systems, and apparatus for tapering or uptitrating drug dosages |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
HU229705B1 (en) * | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
CA2386794A1 (en) * | 2000-07-13 | 2002-01-24 | Euro-Celtique, S.A. | Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
DE60230632D1 (de) * | 2001-07-18 | 2009-02-12 | Euro Celtique Sa | Pharmazeutische kombinationen von oxycodon und naloxon |
US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
US20070232638A1 (en) * | 2006-04-03 | 2007-10-04 | Howard Brooks-Korn | Opiopathies |
WO2009132313A2 (en) * | 2008-04-25 | 2009-10-29 | Progenics Pharmaceuticals, Inc. | Morphinan derivatives of organic and inorganic acids |
BRPI0910780A2 (pt) * | 2008-07-07 | 2016-08-09 | Euro Celtique Sa | uso de antagonistas de opióides para o tratamento da retenção urinária |
DK2405915T3 (en) * | 2009-03-10 | 2019-02-11 | Euro Celtique Sa | PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
KR101632858B1 (ko) * | 2010-12-28 | 2016-06-22 | 유로-셀티큐 에스.에이. | 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물 |
-
2011
- 2011-12-27 KR KR1020157016070A patent/KR101632858B1/ko active IP Right Grant
- 2011-12-27 EA EA201390977A patent/EA025747B1/ru not_active IP Right Cessation
- 2011-12-27 SG SG2013046610A patent/SG191208A1/en unknown
- 2011-12-27 US US13/976,912 patent/US20140037729A1/en not_active Abandoned
- 2011-12-27 AU AU2011351447A patent/AU2011351447B2/en not_active Ceased
- 2011-12-27 MY MYPI2013002299A patent/MY162895A/en unknown
- 2011-12-27 EP EP11802440.5A patent/EP2658523A1/en not_active Withdrawn
- 2011-12-27 UA UAA201309397A patent/UA109301C2/uk unknown
- 2011-12-27 KR KR1020137019870A patent/KR101618929B1/ko not_active IP Right Cessation
- 2011-12-27 JP JP2013546698A patent/JP5864606B2/ja not_active Expired - Fee Related
- 2011-12-27 BR BR112013016862A patent/BR112013016862A2/pt not_active Application Discontinuation
- 2011-12-27 AR ARP110104969A patent/AR084620A1/es unknown
- 2011-12-27 MX MX2013007622A patent/MX354125B/es active IP Right Grant
- 2011-12-27 TW TW100148974A patent/TWI554271B/zh not_active IP Right Cessation
- 2011-12-27 CN CN201180063522.0A patent/CN103347495B/zh not_active Expired - Fee Related
- 2011-12-27 TW TW105112827A patent/TW201628618A/zh unknown
- 2011-12-27 CA CA2822528A patent/CA2822528C/en not_active Expired - Fee Related
- 2011-12-27 WO PCT/EP2011/074103 patent/WO2012089738A1/en active Application Filing
- 2011-12-27 NZ NZ612837A patent/NZ612837A/en not_active IP Right Cessation
-
2013
- 2013-06-12 ZA ZA2013/04303A patent/ZA201304303B/en unknown
- 2013-06-28 CL CL2013001943A patent/CL2013001943A1/es unknown
-
2015
- 2015-09-18 JP JP2015184577A patent/JP6074003B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103347495A (zh) | 2013-10-09 |
CA2822528A1 (en) | 2012-07-05 |
MX354125B (es) | 2018-02-14 |
KR101632858B1 (ko) | 2016-06-22 |
CA2822528C (en) | 2017-07-18 |
AR084620A1 (es) | 2013-05-29 |
ZA201304303B (en) | 2014-02-26 |
WO2012089738A1 (en) | 2012-07-05 |
JP2014501268A (ja) | 2014-01-20 |
UA109301C2 (uk) | 2015-08-10 |
TW201628618A (zh) | 2016-08-16 |
TWI554271B (zh) | 2016-10-21 |
AU2011351447A1 (en) | 2013-07-25 |
JP5864606B2 (ja) | 2016-02-17 |
KR101618929B1 (ko) | 2016-05-09 |
MX2013007622A (es) | 2013-12-06 |
EA025747B1 (ru) | 2017-01-30 |
CL2013001943A1 (es) | 2013-11-29 |
NZ612837A (en) | 2014-11-28 |
SG191208A1 (en) | 2013-07-31 |
TW201302199A (zh) | 2013-01-16 |
BR112013016862A2 (pt) | 2016-10-04 |
KR20150076262A (ko) | 2015-07-06 |
US20140037729A1 (en) | 2014-02-06 |
JP6074003B2 (ja) | 2017-02-01 |
CN103347495B (zh) | 2017-06-20 |
MY162895A (en) | 2017-07-31 |
KR20130106431A (ko) | 2013-09-27 |
AU2011351447B2 (en) | 2016-02-25 |
JP2016040268A (ja) | 2016-03-24 |
EP2658523A1 (en) | 2013-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
EA201170473A1 (ru) | Морфинановые соединения | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
EP4324479A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
EA201290394A1 (ru) | Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7 | |
ME01532B (me) | Jedinjenja | |
EA201201343A1 (ru) | Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а | |
EA201400246A1 (ru) | Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
WO2012032209A3 (es) | Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora. | |
MY169479A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
CL2013001885A1 (es) | Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08). | |
EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
EA201590221A1 (ru) | Способ усовершенствованного синтеза опиоидов | |
EA201590222A1 (ru) | Способ усовершенствованного синтеза опиоидов | |
EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
UA117154C2 (uk) | Антагоністи s1p3 | |
EA201001162A1 (ru) | Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf | |
JO3128B1 (ar) | بيبرازينو-3-فينيل-اندانيس معالج بالديتوريوم لمعالجة انفصام الشخصية- 1 | |
EA201390653A1 (ru) | Aa антагонисты как усилители когнитивной и моторной функций | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |